SGI-1776 is a potent apoptotic that targets Pim and FLT3 in AML and CLL cells
CAS Number:
1025065-69-3
Purity:
≥98%
Molecular Weight:
405.42
Molecular Formula:
C20H22F3N5O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SGI-1776 is a novel ATP-competitive inhibitor of Pim-1, Pim-2, and Pim-3 (IC50 = 7, 363, and 69 nM, respectively). In addition to inhibiting Pim, this compound also inhibits FLT3 (IC50 = 44 nM). SGI-1776 is also cytotoxic in AML primary cells, regardless of the FLT3 mutation status, which results in Mcl-1 protein decline. SGI-1776 inhibits tumor growth for intermediate EFS T/C activity in 1 of 39 evaluable models.
Physical State :
Solid
Storage :
Store at -20° C
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.61 (Predicted)
pK Values :
pKb: 8.93 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
5 by
JT from
CervantesCervantes-Gomez et al. (PubMed ID 26088877) found that the Pim kinase inhibitor, SGI-1776, combined with Bcl-2 antagonists in malignant chronic lymphocytic leukemia lymphocytes resulted in additive cytotoxicity. -SCBT Publication Review